Sun Piaoyang

Under his leadership, Hengrui evolved from a generic drug manufacturer into China's leading innovative pharma company, with a pipeline of novel oncology, autoimmune, and metabolic disease drugs. The company invests more in R&D than any other Chinese pharmaceutical firm — spending over 20% of revenue on research — and has built research centers in China, the United States, and Europe. Hengrui's transformation mirrors China's broader pharmaceutical industry evolution: from copycat generics to globally competitive innovative drugs. The company has developed novel PD-1 inhibitors, PARP inhibitors, and other targeted oncology therapies that compete directly with products from Merck, Roche, and AstraZeneca in the Chinese market. Sun has also pushed Hengrui's international expansion, licensing drugs to global pharma companies and conducting clinical trials outside China. Sun's management of the R&D pipeline productivity, navigation of China's Volume-Based Procurement policy (which slashed generic drug prices and forced the pivot to innovation), and international licensing deals are the primary drivers of Hengrui's stock. The company represents the leading edge of China's pharmaceutical innovation ambitions.